Hematologic Malignancy
Secondary Central Nervous System Lymphoma
CI-CAN-00003884Explore in graph →
Hematologic9 active trials
- NCIt
- C87797
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003884Explore in graph →
Clinical trials
16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05351593 | Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | recruiting | Phase 1 / Phase 2 | 35 | James RubensteinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05256641 | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas |
| recruiting |
| Phase 2 |
| 15 |
| Baptist Health South FloridaOTHER |
| 1 |
| Mar 3, 2026 |
| clinicaltrials |
| NCT07410520 | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2026source: clinicaltrials